This video presents a detailed pathology case study of a skin biopsy characterized by a dense, inflammatory infiltrate. Initially, the low-power view suggested a differential diagnosis including atypical lymphoid processes (lymphoma/leukemia). However, closer examination revealed a mixture of eosinophils and distinctive large cells featuring reniform (kidney-shaped) or "coffee bean-like" grooved nuclei, leading to the definitive diagnosis of Langerhans Cell Histiocytosis (LCH). The discussion highlights the key architectural and cytological features unique to LCH—specifically, its tendency to pack the papillary dermis and trickle up into the epidermis—and differentiates it from look-alikes like Mastocytosis and Rosai-Dorfman disease. Essential confirmatory immunohistochemical stains (S100, CD1A, Langarin) and advanced molecular testing (BRAF V600E mutation, Cyclin D1) are also reviewed for managing clinical and borderline cases.
Langerhans Cell Histiocytosis: A Pathology Case Review
0:14 Low Power Initial Impression: The initial view of the shaved biopsy shows a dense, blue, inflammatory infiltrate. The differential diagnosis includes atypical lymphoid infiltrates (lymphoma, leukemia) or possibly an exuberant bug bite reaction.
0:44 High Power Diagnostic Features: Closer inspection reveals a polymorphous infiltrate including eosinophils, lymphocytes, and larger cells characterized by reniform (kidney-shaped) or coffee bean-like nuclei with grooves.
1:04 Final Diagnosis & Initial Stains: The morphology supports Langerhans Cell Histiocytosis (LCH). Recommended initial confirmatory stains are S100 and CD1A.
1:38 Architectural Clue (Papillary Dermis): LCH typically fills the papillary dermis with cells. The presenter notes that only two common diseases tend to pack the papillary dermis this way: LCH and Mastocytosis.
2:04 Differentiating LCH from Mastocytosis: LCH cells also typically trickle up into the epidermis, not respecting the dermal-epidermal junction (which makes sense as Langerhans cells naturally reside in the spinous layer). Mass cells (mastocytosis) do not exhibit this upward migration.
2:41 Cytological Differentiation: LCH nuclei are characteristically grooved, reniform, or bean-shaped. Mass cells have more oval nuclei and contain granules (though often hard to see on H&E). Eosinophils are usually abundant in LCH.
3:11 Immunohistochemistry (IHC): LCH is S100 positive.
3:19 Differentiating LCH and Rosai-Dorfman: The presenter cautions that while both are S100 positive histiocytic processes often taught together, they rarely look alike in real practice (LCH is typically superficial in the papillary dermis; Rosai-Dorfman is usually deep in the subcutis).
4:05 Specific LCH Markers: CD1A and Langarin (CD207) are specific markers for Langerhans cells. Langarin serves as a surrogate marker for Birbeck granules (which are visualized via electron microscopy, a technique rarely used for routine skin biopsies anymore).
4:33 Clinical Context: LCH can present in varied ways (skin-only, or involving bone/lung). Patients require a clinical workup as the prognosis can range from indolent to aggressive.
5:22 Borderline Cases: For cases where LCH must be differentiated from benign reactive Langerhans cell microabscesses within spongiotic dermatitis, Cyclin D1 IHC may be helpful (positive in LCH, negative in reactive cells).
5:54 Molecular Pathology: LCH often contains an activating BRAF V600E mutation (the same mutation found in many melanomas). Detecting this mutation supports the LCH diagnosis, though it is also found in other histiocytoses (e.g., Chester disease).
6:42 Cytology Review: The discussion concludes by reviewing images showing the upward scatter of cells (which could mimic S100-positive melanoma/pagetoid spread, but LCH is SOX10 negative) and the classic bean-shaped or grooved nuclei.